Imperial College London

Peter Openshaw - Professor of Experimental Medicine

Faculty of MedicineNational Heart & Lung Institute

Proconsul, Professor of Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3854p.openshaw Website CV

 
 
//

Assistant

 

Ms Gale Lewis +44 (0)20 7594 0944

 
//

Location

 

353Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Geretti:2020:cid/ciaa1605,
author = {Geretti, AM and Stockdale, AJ and Kelly, SH and Cevik, M and Collins, S and Waters, L and Villa, G and Docherty, A and Harrison, EM and Turtle, L and Openshaw, PJM and Baillie, JK and Sabin, CA and Semple, MG},
doi = {cid/ciaa1605},
journal = {Clinical Infectious Diseases},
pages = {e2095--e2106},
title = {Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study.},
url = {http://dx.doi.org/10.1093/cid/ciaa1605},
volume = {73},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: Evidence is conflicting about how HIV modulates COVID-19. We compared the presentation characteristics and outcomes of adults with and without HIV who were hospitalized with COVID-19 at 207 centers across the United Kingdom and whose data were prospectively captured by the ISARIC WHO CCP study. METHODS: We used Kaplan-Meier methods and Cox regression to describe the association between HIV status and day-28 mortality, after separate adjustment for sex, ethnicity, age, hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, ten individual comorbidities, and disease severity at presentation (as defined by hypoxia or oxygen therapy). RESULTS: Among 47,592 patients, 122 (0.26%) had confirmed HIV infection and 112/122 (91.8%) had a record of antiretroviral therapy. At presentation, HIV-positive people were younger (median 56 versus 74 years; p<0.001) and had fewer comorbidities, more systemic symptoms and higher lymphocyte counts and C-reactive protein levels. The cumulative day-28 mortality was similar in the HIV-positive vs. HIV-negative groups (26.7% vs. 32.1%; p=0.16), but in those under 60 years of age HIV-positive status was associated with increased mortality (21.3% vs. 9.6%; p<0.001 [log-rank test]). Mortality was higher among people with HIV after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01-2.14; p=0.05), and the association persisted after adjusting for the other variables (aHR 1.69; 95% CI 1.15-2.48; p=0.008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70-4.84; p<0.001). CONCLUSIONS: HIV-positive status was associated with an increased risk of day-28 mortality among patients hospitalized for COVID-19.
AU - Geretti,AM
AU - Stockdale,AJ
AU - Kelly,SH
AU - Cevik,M
AU - Collins,S
AU - Waters,L
AU - Villa,G
AU - Docherty,A
AU - Harrison,EM
AU - Turtle,L
AU - Openshaw,PJM
AU - Baillie,JK
AU - Sabin,CA
AU - Semple,MG
DO - cid/ciaa1605
EP - 2106
PY - 2020///
SN - 1058-4838
SP - 2095
TI - Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study.
T2 - Clinical Infectious Diseases
UR - http://dx.doi.org/10.1093/cid/ciaa1605
UR - https://www.ncbi.nlm.nih.gov/pubmed/33095853
UR - https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1605/5937133
UR - http://hdl.handle.net/10044/1/84592
VL - 73
ER -